Applied Therapeutics (APLT)

• Market cap: $74.4M
• 1 day: -7.41%
• 5 days: -21.94%
• 1 month: -44.37%
• 3 months: -92.80%
• 6 months: -89.23%
• Year to date: -28.77%
• 1 year: -74.41%
• 5 years: -98.62%
• 10 years: -93.19%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Employees: 37

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

220% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 15

92% more capital invested

Capital invested by funds: $501M [Q2] → $961M (+$460M) [Q3]

34% more funds holding

Funds holding: 93 [Q2] → 125 (+32) [Q3]

4.18% more ownership

Funds ownership: 94.0% [Q2] → 98.19% (+4.18%) [Q3]

3% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 31

0% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]

2% less call options, than puts

Call options by funds: $17.1M | Put options by funds: $17.5M

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1.50 134% upside
• Avg. target: $4.13 545% upside
• High target: $8 1,150% upside

4 analyst ratings

• positive: 2 50%
• neutral: 2 50%
• negative: 0 0%

RBC Capital Brian Abrahams 18% 1-year accuracy 14 / 79 met price target	134% upside $1.50	Sector Perform Maintained	20 Dec 2024
UBS Esther Rajavelu 33% 1-year accuracy 1 / 3 met price target	213% upside $2	Neutral Downgraded	2 Dec 2024
Citigroup Yigal Nochomovitz 20% 1-year accuracy 9 / 45 met price target	1,150% upside $8	Buy Maintained	29 Nov 2024
Baird Brian Skorney 17% 1-year accuracy 4 / 24 met price target	681% upside $5	Outperform Maintained	29 Nov 2024